logo
logo

Obatala Sciences Closes $3 Million Series A Funding Round Co-Led By Être Venture Capital And Ochsner Health

Obatala Sciences Closes $3 Million Series A Funding Round Co-Led By Être Venture Capital And Ochsner Health

10/13/22, 12:07 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgnew orleans
Money raised
$3 million
Industry
biotechnology
health care
Round Type
series a
Obatala Sciences, a New Orleans biotechnology company recognized for speeding up therapies for obesity, diabetes, and cancer across diverse populations, today announced the closing of a $3 million Series A finance round co-led by être Venture Capital and Ochsner Lafayette General Healthcare Innovation Fund II and joined by Benson Capital Partners, Elevate Capital Fund, and The Hackett-Robertson-Tobe Group.

Company Info

Company
Obatala Sciences
Location
new orleans, louisiana, united states
Additional Info
Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include major pharmaceutical companies, US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell™, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.

Related People